Khandelwal A, Gorsi U, Marginean EC, Papadatos D, George U

Idioma: Ingles.
Referencias bibliográficas: 8
Paginas: 332-335
Archivo PDF: 514.99 Kb.

RESUMEN

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-619.

2. Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 3123-35.

3. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008; 48: 1106-17.

4. Chung YE, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC, Cho HJ, et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29: 683-700.

5. Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN. Mimics of cholangiocarcinoma: spectrum of disease. Radiographics 2008; 28: 1115-29.

6. Braun M, Fraser GM, Kunin M, Salamon F. Mesalamine induced granulomatous hepatitis. Am J Gastro1999; 94: 1973-4.

7. Maetani Y, Itoh K, Watanabe C, Shibata T, Ametani F, Yamabe H , Konishi J. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 2001; 176: 1499-507.

8. Balci NC, Tunaci A, Akinci A, Cevikbas U. Granulomatous hepatitis: MRI findings. Magn Reson Imaging 2001; 19: 1107-11.